KRAS and neoplasm: These findings were consistent across a variety of experimental models, including an established KRAS mutated MUC2‐secreting colon cancer cell line (LS174T), as well as patient‐derived tumor explants, colonoid cultures, and murine IP xenografts of KRAS mutated mucinous colon/appendix cancers.